中國投資開發(00204.HK):近期與中盈華夏簽訂戰略合作意向書
格隆匯5月31日丨中國投資開發(00204.HK)公佈,公司近期與中盈華夏(深圳)投資集團有限公司(“中盈華夏”)簽訂了戰略合作意向書。
中盈華夏是中盈國際控股(廣東)有限公司旗下全資附屬企業。中盈華夏致力建設協助及推動香港上市公司及國內企業相互合作的平台,該公司幫助國內中小企業進行股權重整、加強企業治理機制及提高價值創造能力,以期能與國際資本市場接軌。
公司認為,該意向書擬進行的戰略合作符合集團的長期發展目標及業務發展策略。本次與中盈華夏的戰略合作可為雙方帶來潛在的利潤增長點,此舉符合公司及股東的整體利益。正式協議的具體條款和條件需要待公司完成盡職調查後由董事會進行審批。若有進展,公司將於適當時候遵照香港聯合交易所有限公司上市規則作進一步公吿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.